Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients

European Journal of Clinical Pharmacology

Volumn 69, Issue 8, 2013, Pages 1511-1519

  Kang, Yan Hong ^a   Lao, Hai Yan ^a   Wu, Hong ^b   Lai, Wei Hua ^a   Li, Xin Xin ^a   Yu, Xi Yong ^a   Chen, Ji Yan ^a   Zhong, Shi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bleeding; Coronary artery disease; Dual antiplatelet therapy; Genetic variant; Major adverse cardiac event; Paraoxonase 1

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOCHROME P450 2C19 GENE; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HEART DISEASE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARAOXONASE 1 GENE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION;

AGED; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROMOTER REGIONS, GENETIC; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84880514104     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1516-6     Document Type: Article

References (27)

1. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265-1276
2. Gupta N, Binu KB, Singh S, Maturu NV, Sharma YP, Bhansali A, Gill KD (2012) Low serum PON1 activity: an independent risk factor for coronary artery disease in North-West Indian type 2 diabetics. Gene 498:13-19
3. Mohamed RH, Karam RA, Abd El-Aziz TA (2010) The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 43:553-558
4. Dunet V, Ruiz J, Allenbach G, Izzo P, James RW, Prior JO (2011) Effects of paraoxonase activity and gene polymorphism on coronary vasomotion. EJNMMI Res 1:27
5. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD (2011) Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One 6:e17805
6. Wang M, Lang X, Zou L, Huang S, Xu Z (2011) Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis 214:377-385
7. Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz H-G, ten Berg JM, Taubert D (2010) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110-116
8. Tselepis AD, Tsoumani ME, Kalantzi KI, Dimitriou AA, Tellis CC, Goudevenos IA (2011) Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J Thromb Haemost 9:2371-2378
9. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, van der Graaf Y (2009) Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 54:1238-1245
10. Zhao LP, Li SS, Khalid N (2003) A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 72:1231-1250
11. Moura LM, Faria S, Brito M, Pinto FJ, Kristensen SD, Barros IM, Rajamannan N, Rocha-Goncalves F (2012) Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. Am J Cardiovasc Dis 2:123-132
12. Ahmad I, Narang R, Venkatraman A, Das N (2012) Two- and three-locus haplotypes of the paraoxonase (PON1) gene are associated with coronary artery disease in Asian Indians. Gene 506:242-247
13. Wang Y, Fu W, Xie F, Chu X, Wang H, Shen M, Sun W, Lei R, Yang L, Wu H, Foo J, Liu J, Jin L, Huang W (2010) Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population. J Hum Genet 55:490-494
14. Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, Tanck MW, Wareham NJ, Jukema JW, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One 4:e6809
15. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001) Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436
16. Arii K, Suehiro T, Ota K, Ikeda Y, Kumon Y, Osaki F, Inoue M, Inada S, Ogami N, Takata H, Hashimoto K, Terada Y (2009) Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 202:439-445
17. Arii K, Suehiro T, Ikeda Y, Kumon Y, Inoue M, Inada S, Takata H, Ishibashi A, Hashimoto K, Terada Y (2010) Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Metabolism 59:1287-1293
18. Osaki F, Ikeda Y, Suehiro T, Ota K, Tsuzura S, Arii K, Kumon Y, Hashimoto K (2004) Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 176:279-287
19. Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y (2012) The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol 166:2362-2370
20. Reny JL, Combescure C, Daali Y, Fontana P (2012) Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 10:1242-1251
21. Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, Schiele F, Ferrari E, Drouet E, Grollier G, Danchin N (2011) Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 90:561-567
22. Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, Degorter MK, Woolsey S, Tirona RG, Kim RB (2012) Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J 3(22):2856-2464a
23. Shuldiner AR, Vesely MR, Fisch A (2012) CYP2C19 genotype and cardiovascular events. JAMA 307:1482, author reply 1484-1485
24. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830
25. Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ (2012) Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59:1928-1937
26. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD, Rao SV, Verheugt FW, Widimsky P, Zeymer U, Collet JP (2011) Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 32:1854-1864
27. Santanam N, Parthasarathy S (2007) Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis 191:272-275